Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.51 |
| ▸ | TTK | P33981 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7121927 | 0.88 | F10 (0.46) | F10TTKMAPTF2MAPK8 | |
| SCHEMBL7119306 | 0.85 | RAB9A (0.41) | F10TP53MAPTPOLBCA1 | |
| SCHEMBL7128478 | 0.82 | F10 (0.54) | F10TTKF2CA1CA2 | |
| SCHEMBL7122557 | 0.80 | F10 (0.55) | F10TTKTP53F2MAPK8 | |
| SCHEMBL7121882 | 0.73 | RAB9A (0.38) | TTKMAPTMAPK8 | |
| SCHEMBL7119405 | 0.71 | F10 (0.48) | F10F2 | |
| SCHEMBL7119005 | 0.70 | F10 (0.49) | F10F2 | |
| SCHEMBL7126891 | 0.68 | F10 (1.00) | F10F2 | |
| SCHEMBL7129114 | 0.67 | MGLL (0.37) | TTKMAPTMAPK8 | |
| SCHEMBL11001879 | 0.65 | CA1 (0.50) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114448-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114448-A1 | Inhibitors of factor Xa | SERPINC1, F11, TFPI | F10 7/4885TTK 3731/4885TP53 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.